Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study.

Siemieniuk RA, Gregson DB, Gill MJ.

BMC Infect Dis. 2011 Nov 11;11:314. doi: 10.1186/1471-2334-11-314.

2.

Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era.

Munier AL, de Lastours V, Porcher R, Donay JL, Pons JL, Molina JM.

Int J STD AIDS. 2014 Dec;25(14):1022-8. doi: 10.1177/0956462414528316. Epub 2014 Mar 27.

PMID:
24676129
3.

Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.

Grau I, Ardanuy C, Liñares J, Podzamczer D, Schulze MH, Pallares R.

HIV Med. 2009 Sep;10(8):488-95. doi: 10.1111/j.1468-1293.2009.00717.x. Epub 2009 May 6.

4.

Invasive pneumococcal disease among HIV-positive individuals, 2000-2009.

Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC.

AIDS. 2012 Jan 2;26(1):87-94. doi: 10.1097/QAD.0b013e32834dcf27.

PMID:
22008657
5.

Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.

Steenhoff AP, Wood SM, Rutstein RM, Wahl A, McGowan KL, Shah SS.

Pediatr Infect Dis J. 2008 Oct;27(10):886-91. doi: 10.1097/INF.0b013e3181734f8f.

PMID:
18776825
6.

Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children.

Burgos J, Peñaranda M, Payeras A, Villoslada A, Curran A, Garau M, Riera M, Crespo M, Navarro J, Van den Eynde E, Planes AM, Ribera E, Pahissa A, Falcó V.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):31-8. doi: 10.1097/QAI.0b013e31823d0f5f.

PMID:
22156821
7.

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103).

Arch Intern Med. 2005 Jul 11;165(13):1533-40.

PMID:
16009870
8.

A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.

Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC.

HIV Med. 2010 Jan;11(1):54-63. doi: 10.1111/j.1468-1293.2009.00744.x. Epub 2009 Jul 29.

9.

Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination.

Munier AL, de Lastours V, Varon E, Donay JL, Porcher R, Molina JM.

Infection. 2013 Jun;41(3):663-8. doi: 10.1007/s15010-013-0419-x. Epub 2013 Feb 13.

PMID:
23404685
11.

The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes.

Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD, Harrison C, Bayley K, Watson M, Richmond P.

Clin Infect Dis. 2010 Jun 1;50(11):1477-86. doi: 10.1086/652440.

PMID:
20420501
12.

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, Borkowsky W, Rosenblatt HM, Marcinak JF, Dieudonne A, Abrams EJ, Pathak I; Pediatric AIDS Clinical Trials Group P1024 Protocol Team.

Pediatr Infect Dis J. 2006 Oct;25(10):920-9.

PMID:
17006288
13.

Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.

PMID:
19508165
14.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
15.

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010.

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060. Epub 2012 Apr 11.

PMID:
22504662
16.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
17.

Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.

Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health.

Pediatr Infect Dis J. 2010 Apr;29(4):289-93. doi: 10.1097/INF.0b013e3181c15471.

PMID:
19935447
18.

Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.

Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL.

Clin Infect Dis. 2010 May 1;50(9):1238-46. doi: 10.1086/651680.

PMID:
20367225
20.

Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003.

Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM.

AIDS. 2006 Feb 14;20(3):437-44.

PMID:
16439878

Supplemental Content

Support Center